Schedule II & RFK ·
The HHS peptide policy review opened a public comment period in fall 2025, generating thousands of submissions from researchers, clinicians, patients, and industry stakeholders. Comments have clustered around several themes: expanded access for research, clarified pathways for legitimate clinical use, stronger enforcement against bad actors in the research peptide retail space, and more consistent state-federal coordination. RFK Jr. personally highlighted several comments in subsequent public remarks, and the HHS staff has committed to addressing major themes in the forthcoming policy recommendations expected in mid-2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.